Repurposing pemafibrate to treat liver disease associated with metabolic disorders

FHS
July 10, 2024
7:20 pm

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people.

Novo, Lilly shares sink due to concerns over competition

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hellloooooo. Today, we discuss

July 19, 2024

House Democrats push back on Republicans’ drug shortage proposals during legislative hearing

House lawmakers have returned from recess with their work cut out for them to address ongoing drug shortages, but reaching bipartisan consensus on how to

September 15, 2023

Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s

February 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.